Viés de alta
Endo International Bullish News | Upside Potential
Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized generic versions of Mallinckrodt's Amitiza® (lubiprostone) 8 mcg and 24 mcg capsules.
According to IQVIA™, Amitiza® capsule sales were approximately $427 million for the 12 months ended September 30, 2020. (Source: prnewswire.com)
Endo International plc (NASDAQ: ENDP) announced that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. (Source: newswire.ca)
"We are very pleased to work with Radius to possibly bring a new treatment option to the market for Canadian osteoporosis patients," said Livio Di Francesco, Vice President and General Manager of Paladin.
Please leave me a message if you want to test the buy and sell indicators that i am using.
According to IQVIA™, Amitiza® capsule sales were approximately $427 million for the 12 months ended September 30, 2020. (Source: prnewswire.com)
Endo International plc (NASDAQ: ENDP) announced that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. (Source: newswire.ca)
"We are very pleased to work with Radius to possibly bring a new treatment option to the market for Canadian osteoporosis patients," said Livio Di Francesco, Vice President and General Manager of Paladin.
Please leave me a message if you want to test the buy and sell indicators that i am using.
Copy my trades: partner.bybit.com/b/best_copy_trading
BUY-SELL INDICATORS: bit.ly/indicatorz
TRADING COURSE: bit.ly/10Xtrading
STOCK OPTIONS SIGNALS: bit.ly/options_signals
BUY-SELL INDICATORS: bit.ly/indicatorz
TRADING COURSE: bit.ly/10Xtrading
STOCK OPTIONS SIGNALS: bit.ly/options_signals
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.